Crizotinib
- TRADE NAME: Xalkori (Pfizer)
- INDICATIONS: Advanced or metastatic non-small cell lung cancer in ALK-positive patients
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor, MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 42 hours
Alfentanil, Atazanavir, Carbamazepine, Clarithromycin, Cyclosporine, CYP3A4 inducers, inhibitors or substrates, Dihydroergotamine, Efavirenz, Ergotamine, Fentanyl, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Neratinib, Olaparib, Phenobarbital, Phenytoin, Pimozide, Quinidine, Rifabutin, Rifampin, Ritonavir, Saquinavir, Sirolimus, St John's Wort, Tacrolimus, Telithromycin, Troleandomycin, Voriconazole
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of crizotinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 12/06/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric